Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma
Caroline Robert(Institut Gustave Roussy), Dirk Schadendorf(National Center for Tumor Diseases), Jacob Schachter, Andrzej Maćkiewicz(Poznan University of Medical Sciences), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Stephen Lane(Novartis (United States)), Y. Zhang(Jiangsu Cancer Hospital), Axel Hauschild(University Hospital Schleswig-Holstein), Florent Grange(Hôpital Lyon Sud), Daniil Stroyakovskiy(Shikoku Cancer Center), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Laurent Mortier, Bijoyesh Mookerjee(Novartis (United States)), Bogusława Karaszewska(State University of Applied Sciences in Konin), Reinhard Dummer(University Hospital of Zurich), Ivana Krajsová(Charles University), Jeffery J. Legos(Novartis (United States)), Kamil Drucis(Apple (Israel))
Cited by 74
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k